Agios Pharmaceuticals Inc. Stock
There is an upward development for Agios Pharmaceuticals Inc. compared to yesterday, with an increase of €0.60 (1.950%).
With 20 Buy predictions and not the single Sell prediction the community is currently very high on Agios Pharmaceuticals Inc..
As a result the target price of 35 € shows a positive potential of 23.24% compared to the current price of 28.4 € for Agios Pharmaceuticals Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Agios Pharmaceuticals Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Agios Pharmaceuticals Inc. in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Agios Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc. | 1.950% | -10.692% | -12.883% | -13.415% | 22.414% | 17.355% | -32.670% |
| Ligand Pharmaceuticals | -1.540% | -3.759% | -7.246% | 118.803% | 54.217% | 316.260% | 167.056% |
| United Therapeutics | -0.520% | -2.019% | -3.756% | 84.880% | 6.740% | 104.989% | 194.258% |
| Ionis Pharmaceuticals Inc. | -1.480% | -5.964% | -34.579% | 21.707% | -32.019% | 27.978% | 47.510% |
Comments
Agios Pharmaceuticals (AGIO) had its price target raised by HC Wainwright from $52.00 to $55.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals (AGIO) had its price target lowered by HC Wainwright from $54.00 to $52.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals (AGIO) had its price target raised by Truist Financial Corporation from $36.00 to $41.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
News
Agios Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Agios Pharmaceuticals, Inc.? Here are five stocks we like better.
- Mitapivat revenue reached $44.7 million in Q2 2026, while Agios reported a $100.7 million net loss
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week
Agios Pharmaceuticals (NASDAQ: AGIO) stock rose by 13.8% during the week through Friday morning. It's a move driven by the Food and Drug Administration's (FDA) announcement that it would grant
Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) were higher by more than 14% as of 11 a.m this morning. The move comes after a very positive development from the Food and Drug Administration (FDA) on